

Cassandra Calabrese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594023/publications.pdf>

Version: 2024-02-01

23
papers

803
citations

623734

14
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

1616
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccinations in Patients with Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 397-409.	1.9	0
2	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.9	29
3	Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. <i>Rheumatology</i> , 2021, 60, 5149-5157.	1.9	19
4	The intersection of COVID-19 and autoimmunity: What is our current understanding?. <i>Pathogens and Immunity</i> , 2021, 6, 31-54.	3.1	20
5	Vaccinations in Patients with Rheumatic Disease. <i>Medical Clinics of North America</i> , 2021, 105, 213-225.	2.5	5
6	COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review. <i>Pathogens and Immunity</i> , 2021, 6, 76-103.	3.1	56
7	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 "Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
8	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
9	Infections in the Era of Targeted Therapies: Mapping the Road Ahead. <i>Frontiers in Medicine</i> , 2020, 7, 336.	2.6	5
10	Mycobacterial Infections Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 413-423.	5.1	4
11	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	27.6	189
12	The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. <i>Current Opinion in Rheumatology</i> , 2020, 32, 175-183.	4.3	1
13	Practical aspects of targeting IL-6 in COVID-19 disease. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	1.3	18
14	Rheumatological Toxicities of Immunotherapy. , 2020, , 277-286.		0
15	Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS). <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e791.	1.2	21
16	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 860-862.	0.9	14
17	Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. <i>RMD Open</i> , 2019, 5, e000906.	3.8	59
18	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 177-182.	1.9	11

#	ARTICLE	IF	CITATIONS
19	A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-9.	0.6	2
20	Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019, 37, e14151-e14151.	1.6	19
21	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	8.0	162
22	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 439-446.	5.6	24
23	Evaluating Indeterminate Interferon- γ Release Assay Results in Patients With Chronic Inflammatory Diseases Receiving Immunosuppressive Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 1063-1069.	3.4	14